Approval
Israel approves ImmunityBio's ANKTIVA with BCG for BCG-unresponsive bladder cancer
Israel's health ministry cleared ANKTIVA, given together with BCG, for adults whose non-muscle-invasive bladder tumours include carcinoma in situ and no longer respond to BCG. The review took four months, and the formal registration license should follow within weeks. Rafa Laboratories will sell the drug in Israel, and the companies count 35 countries where ANKTIVA is now authorized.
- Drugnogapendekin alfa inbakicept
- CompanyRafa Laboratories
- TargetCytokine receptor common subunit gamma
- TargetInterleukin–15 receptor
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.